Outcome and prognosis of anaplastic large cell lymphoma in children: a report from the Taiwan Pediatric Oncology Group

References

• Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med. 1996;334:1238–1248.
   PubMed Web of Science ®Google Scholar
• Wright D, McKeever P, Carter R. Childhood non-Hodgkin lymphomas in the United Kingdom: findings from the UK Children's Cancer Study Group. J Clin Pathol. 1997;50:128–134.
   PubMed Web of Science ®Google Scholar
• Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol. 2001;14:219–228.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–5504.
   PubMed Web of Science ®Google Scholar
• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematol Am Soc Hematol Educ Prog. 2009;2009:523–531.
   Google Scholar
• Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11–23.
   PubMed Web of Science ®Google Scholar
• Liang X, Meech SJ, Odom LF, et al. Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK + anaplastic large cell lymphoma. Am J Clin Pathol. 2004;121:496–506.
   PubMed Web of Science ®Google Scholar
• Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005;104:2133–2140.
   PubMed Web of Science ®Google Scholar
• Lowe EJ, Sposto R, Perkins SL, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer. 2009;52:335–339.
   PubMed Web of Science ®Google Scholar
• Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin–Frankfurt–Münster Group Trial NHL-BFM 90. Blood. 2001;97:3699–3706.
   PubMed Web of Science ®Google Scholar
• Brugieres L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897–903.
   PubMed Web of Science ®Google Scholar
• Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111:1560–1566.
   PubMed Web of Science ®Google Scholar
• Mori T, Kiyokawa N, Shimada H, et al. Anaplastic large cell lymphoma in Japanese children: retrospective analysis of 34 patients diagnosed at the National Research Institute for Child Health and Development. Br J Haematol. 2003;121:94–96.
   PubMed Web of Science ®Google Scholar
• Sun X, Zhen Z, Lin S, et al. Treatment outcome of Chinese children with anaplastic large cell lymphoma by using a modified B-NHL-BFM-90 protocol. Pediatr Hematol Oncol. 2014;31:518–527.
   PubMed Web of Science ®Google Scholar
• Han JY, Suh JK, Lee SW, et al. Clinical characteristics and treatment outcomes of children with anaplastic large cell lymphoma: a single center experience. Blood Res. 2014;49:246–252.
   PubMedGoogle Scholar
• Yang CP, Hung JJ, Jaing TH, et al. Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: a report from the Taiwan Pediatric Oncology Group (TPOG). Acta Paediatr Taiwan. 2000;41:193–204.
   PubMedGoogle Scholar
• Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392.
   PubMed Web of Science ®Google Scholar
• Delsol G, Falini B, Muller-Hermelink HK, et al. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC. p. 312–316.
   Google Scholar
• Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332–339.
   PubMed Web of Science ®Google Scholar
• Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24:397–405.
   PubMed Web of Science ®Google Scholar
• Lee MY, Tan TD, Feng AC, et al. Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution. Am J Hematol. 2006;81:568–575.
   PubMed Web of Science ®Google Scholar
• Lowe EJ, Gross TG. Anaplastic large cell lymphoma in children and adolescents. Pediatr Hematol Oncol. 2013;30:509–519.
   PubMed Web of Science ®Google Scholar
• Yang HB, Li J, Shen T. Primary anaplastic large cell lymphoma of the lung. Report of two cases and literature review. Acta Haematol. 2007;118:188–191.
   PubMed Web of Science ®Google Scholar
• Etienne B, Guillaud PH, Loire R, et al. Aggressive primary mediastinal non-Hodgkin's lymphomas: a study of 29 cases. Eur Respir J. 1999;13:1133–1138.
   PubMed Web of Science ®Google Scholar
• Gu TL, Tothova Z, Scheijen B, et al. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood. 2004;103:4622–4629.
   PubMed Web of Science ®Google Scholar
• Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2007;110:670–677.
   PubMed Web of Science ®Google Scholar
• Damm-Welk C, Mussolin L, Zimmermann M, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123:334–337.
   PubMed Web of Science ®Google Scholar
• Ait-Tahar K, Damm-Welk C, Burkhardt B, et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood. 2010;115:3314–3319.
   PubMed Web of Science ®Google Scholar
• Brugieres L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27:5056–5061.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29:3065–3071.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents—a Berlin–Frankfurt–Münster group report. Br J Haematol. 2006;133:176–182.
   PubMed Web of Science ®Google Scholar
• Fukano R, Mori T, Kobayashi R, et al. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan. Br J Haematol. 2015;168:557–563.
   PubMed Web of Science ®Google Scholar
• Ceppi F, Ortiz R, Antillon F, et al. Anaplastic large cell lymphoma in Central America: a report from the Central American Association of Pediatric Hematology Oncology (AHOPCA). Pediatr Blood Cancer. 2016;63:78–82.
   PubMed Web of Science ®Google Scholar
• Turner SD, Lamant L, Kenner L, et al. Anaplastic large cell lymphoma in paediatric and young adult patients. Br J Haematol. 2016;173:560–572.
   PubMed Web of Science ®Google Scholar
• Mikles B, Levine J, Gindin T, et al. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma. J Pediatr Hematol Oncol. 2014;36:e85–e87.
   PubMed Web of Science ®Google Scholar
• Koh KN, Im HJ, Suh JK, et al. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation. Pediatr Blood Cancer. 2015;62:1063–1065.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364:775–776.
   PubMed Web of Science ®Google Scholar
• Gambacorti Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014;106:djt378.
   PubMedGoogle Scholar
• Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14:472–480.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Mussolin L, Brugieres L. Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib. N Engl J Med. 2016;374:95–96.
   PubMed Web of Science ®Google Scholar